const  NeuroPace =
{
    "company": {
      "name": "NeuroPace, Inc.",
      "focus": "Brain-responsive neuromodulation for drug-resistant focal epilepsy",
      "product": "RNS System",
      "target_population": "Approximately 1 million U.S. patients with drug-resistant epilepsy, focusing on focal onset seizures",
      "sales_channel": "Level 4 Comprehensive Epilepsy Centers (CECs)"
    },
    "financials": {
      "full_year_revenue": {
        "2024": {
          "total": 76000000,
          "growth_rate": "16.2%",
          "compared_to": 65424000
        },
        "2023": {
          "total": 65424000,
          "growth_rate": "43.6%",
          "compared_to": 45516000
        },
        "2022": {
          "total": 45516000,
          "growth_rate": "0.7%",
          "compared_to": 45205000
        },
        "2021": {
          "total": 45205000,
          "growth_rate": "10.0%",
          "compared_to": 41137000
        }
      },
      "q4_revenue": {
        "2024": {
          "total": 20000000,
          "growth_rate": "14.3%",
          "compared_to": 17500000,
          "breakdown": {
            "initial_implants": {
              "amount": 17500000,
              "growth_rate": "16.7%",
              "compared_to": 15000000
            },
            "replacement_implants": {
              "amount": 2500000,
              "growth_rate": "0%",
              "compared_to": 2500000
            }
          }
        },
        "2023": {
          "total": 17500000,
          "growth_rate": "23.2%",
          "compared_to": 14200000,
          "breakdown": {
            "initial_implants": {
              "amount": 15000000
            },
            "replacement_implants": {
              "amount": 2500000
            }
          }
        },
        "2022": {
          "total": 14200000,
          "growth_rate": "29.1%",
          "compared_to": 11000000
        }
      },
      "revenue_guidance_2025": {
        "range": {
          "min": 87000000,
          "max": 91000000
        },
        "growth_rate": "14.5% to 19.7%",
        "compared_to": 76000000
      },
      "gross_margin": {
        "2024": "73.6%",
        "q4_2024": "73.7%",
        "2023": "73.8%",
        "2022": "72.0%"
      },
      "operating_expenses": {
        "2024": 80800000,
        "q4_2024": 20900000,
        "2023": 74900000
      },
      "r_and_d_expenses": {
        "2024": 34800000,
        "q4_2024": 8800000,
        "2023": 32700000,
        "2022": 31900000
      },
      "net_loss": {
        "2024": 27600000,
        "q4_2024": 6700000,
        "2023": 32957000,
        "2022": 47083000
      },
      "cash_position": {
        "dec_31_2024": 141900000
      }
    },
    "sales_data": {
      "revenue_composition_q4_2024": {
        "initial_implants": {
          "amount": 17500000,
          "percentage_of_total": "87.5%"
        },
        "replacement_implants": {
          "amount": 2500000,
          "percentage_of_total": "12.5%"
        }
      },
      "revenue_composition_q4_2023": {
        "initial_implants": {
          "amount": 15000000,
          "percentage_of_total": "85.7%"
        },
        "replacement_implants": {
          "amount": 2500000,
          "percentage_of_total": "14.3%"
        }
      },
      "sales_growth_drivers": [
        "Increased adoption at Level 4 CECs",
        "Expansion of commercial sales team in 2024",
        "Enhanced clinician education and patient referral programs"
      ]
    },
    "growth_metrics": {
      "annual_growth_rates": {
        "2024_vs_2023": "16.2%",
        "2023_vs_2022": "43.6%",
        "2022_vs_2021": "0.7%"
      },
      "q4_growth_rates": {
        "2024_vs_2023": "14.3%",
        "2023_vs_2022": "23.2%"
      },
      "clinical_growth_indicator": {
        "study": "Post-approval study",
        "result": "82% median reduction in seizure frequency over 3 years",
        "presentation_date": "April 7, 2025",
        "event": "American Academy of Neurology (AAN) meeting"
      }
    },
    "additional_insights": {
      "q3_2024_revenue": {
        "total": 19400000,
        "growth_rate": "13.5%",
        "compared_to": 17100000
      },
      "cumulative_q1_q3_2024_revenue": {
        "total": 56000000,
        "growth_rate": "16.9%",
        "compared_to": 47900000
      },
      "market_opportunity": "Approximately 575,000 U.S. patients with drug-resistant focal epilepsy",
      "device_longevity": "Average battery life of RNS System ~11 years"
    }
  }

  export default NeuroPace